Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY)

Summary

Shuxuening injection is a multi-target neuroprotective agent, it is expected to play a neuroprotective role on the basis of intravenous thrombolysis therapy. The primary purpose of this multicenter, randomized, double-blind, placebo-parallel controlled trial is to evaluate the efficacy and safety of Shuxuening injection in the treatment with intravenous thrombolysis in patients with ischemic stroke.

Timeline

Start

2024-01-11

Primary completion

2025-12-31

Completion

2026-07-31

Publications

• Wang A, Li J, Zhang X, Xia X, Wang Y. Rationale and design of Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY): A multicenter randomized trial. Brain Circ. 2025 Nov 3;12(1):1-6. doi: 10.4103/bc.bc_65_25. eCollection 2026 Jan-Mar.

Drugs

Indications